117 related articles for article (PubMed ID: 11267244)
1. Effects of angiotensin-converting-enzyme inhibitors on progression to end-stage renal failure in chronic vascular rejection.
Rustom R; Paraoan MT; Sells RA; Jackson MJ; Hammad A; Bakran A; Brown M; Ahmad RA; Williams PS; Bell GM; Sharma A; Bone JM
Transplant Proc; 2001; 33(1-2):1175-6. PubMed ID: 11267244
[No Abstract] [Full Text] [Related]
2. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
3. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
[TBL] [Abstract][Full Text] [Related]
4. Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys.
Neild GH; Thomson G; Nitsch D; Woolfson RG; Connolly JO; Woodhouse CR
BMC Nephrol; 2004 Oct; 5():12. PubMed ID: 15462683
[TBL] [Abstract][Full Text] [Related]
5. REIN on obesity, proteinuria and CKD.
Choi ME
J Am Soc Nephrol; 2011 Jun; 22(6):990-2. PubMed ID: 21617125
[No Abstract] [Full Text] [Related]
6. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure.
Barnas U; Schmidt A; Haas M; Oberbauer R; Mayer G
Nephrol Dial Transplant; 1996 Sep; 11(9):1822-4. PubMed ID: 8918629
[No Abstract] [Full Text] [Related]
7. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; Marcantoni C; de Jong PE; de Zeeuw D; Shahinfar S; Ruggenenti P; Remuzzi G; Levey AS;
Kidney Int; 2001 Sep; 60(3):1131-40. PubMed ID: 11532109
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of evidence-based medicine: searching.
Spier BJ; Feldstein DA
WMJ; 2006 Jul; 105(5):9-11. PubMed ID: 16933405
[No Abstract] [Full Text] [Related]
10. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.
Szabo A; Lutz J; Schleimer K; Antus B; Hamar P; Philipp T; Heemann U
Kidney Int; 2000 Mar; 57(3):982-91. PubMed ID: 10720951
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
Hirsch S
Compr Ther; 2009; 35(2):91-5. PubMed ID: 19618757
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy.
Moscoso-Solorzano GT; Mastroianni-Kirsztajn G; Ozaki KS; Franco MF; Pacheco-Silva A; Câmara NO
Braz J Med Biol Res; 2009 May; 42(5):445-52. PubMed ID: 19377794
[TBL] [Abstract][Full Text] [Related]
13. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
[TBL] [Abstract][Full Text] [Related]
14. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure.
Zucchelli P; Zuccalà A; Gaggi R
Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():46-51. PubMed ID: 8643208
[No Abstract] [Full Text] [Related]
16. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L
Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190
[TBL] [Abstract][Full Text] [Related]
17. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
[TBL] [Abstract][Full Text] [Related]
18. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?
Cattran DC
J Am Soc Nephrol; 2007 Jun; 18(6):1633-4. PubMed ID: 17494880
[No Abstract] [Full Text] [Related]
19. [How to slow the progression of chronic renal insufficiency].
Rossert J; Ronco P
Rev Prat; 2001 Feb; 51(4):378-84. PubMed ID: 11355601
[TBL] [Abstract][Full Text] [Related]
20. The Remission Clinic approach to halt the progression of kidney disease.
;
J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
